PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
34.57%
Cash & equivalents yoy growth 0.5-0.75x TRVN's 49.87%. Martin Whitman would worry if slower accumulation signals weaker operations or bigger outflows.
68.63%
Short-term investments yoy growth below half of TRVN's -12.45%. Michael Burry might see potential liquidity risk. Investigate alternative capital uses or constraints.
34.59%
Cash + STI yoy ≥ 1.5x TRVN's 5.57%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.58%
≥ 1.5x TRVN's 4.65%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-15.03%
Below half TRVN's 3.25%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.19%
Below half of TRVN's 2.73%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
31.29%
≥ 1.5x TRVN's 4.64%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-18.99%
Less than half of TRVN's 28.83%. David Dodd sees a more disciplined AP approach or lower volume.
-51.38%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-91.88%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
-10.37%
Less than half of TRVN's 4.52%. David Dodd sees fewer expansions in other current obligations.
-15.50%
Less than half of TRVN's 8.71%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.50%
Above 1.5x TRVN's -4.95%. Michael Burry sees a potential leverage warning sign.
13.39%
Above 1.5x TRVN's 6.90%. Michael Burry suspects heavy new equity expansion or dilution.
-7.92%
Similar yoy to TRVN's -7.95%. Walter Schloss sees parallel earnings retention vs. competitor.
-32.48%
Less than half of TRVN's 26.67%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
41.56%
≥ 1.5x TRVN's 6.41%. David Dodd sees stronger capital base growth than competitor.
31.29%
≥ 1.5x TRVN's 4.64%. David Dodd sees faster overall balance sheet growth than competitor.
68.63%
Below half TRVN's -12.45%. Michael Burry suspects major underinvestment or forced divestment.
-51.38%
Less than half of TRVN's 1.64%. David Dodd sees less overall debt expansion vs. competitor.
-35.43%
50-75% of TRVN's -52.91%. Bruce Berkowitz notes comparatively lower net debt expansion.